Novartis has been making news in the investment and biotechnology sector with its recent acquisition of Regulus Therapeutics for $1.7 Billion. This move signals the pharmaceutical giant's interest in expanding its capabilities and market presence. Deutsche Bank and UBS further validate Novartis's strong position by maintaining their hold / buy ratings. The firm's shares are seeing momentum and good relative strength, making it an appealing option for long-term investors. Novartis's impressive Q1 earnings and rising sales have resulted in it boosting full-year guidance. It has been labelled as a promising dividend and undervalued stock, signalling a strong investment case. However, the firm is not without challenges, evident through competition facing its major drug and insider trading scheme linked to one of its acquisitions. Yet, Novartis seems undeterred, showcasing a $23 billion strategic investment plan and announcements of a boost to U.S manufacturing. As per reports, Novartis’s stock ownership is undergoing changes with the Sandoz family foundation offering $3 billion worth of their shares.
Novartis Stocks News Analytics from Tue, 29 Oct 2024 07:00:00 GMT to Sat, 28 Jun 2025 16:41:25 GMT -
Rating 8
- Innovation -2
- Information 9
- Rumor -3
